0

BAVENCIO از شرکت EMD SERONO INC

تصویر پیدا نشد !

اطلاعات داروی نمایش داده شده مستقیما از دیتابیس اطلاعات دارویی سازمان غذا و دارو آمریکا (FDA) استخراج می شود و مرتبا به روز رسانی می شود
داروی نمایش داده شده مورد تایید FDA می باشد و اطلاعات ثبت آن در زیر قابل مشاهده است

BAVENCIO از شرکت EMD SERONO INC

Biologic License Application (BLA): 761049

Company: EMD SERONO INC

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
BAVENCIO AVELUMAB 20MG/ML INJECTABLE;INJECTION Prescription

None

No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
03/23/2017 ORIG-1 Approval

N/A; Orphan

Label (PDF)

Letter (PDF)

Review

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761049Orig1s000ltredt.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000TOC.cfm

Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
06/30/2020 SUPPL-9 Supplement

Label (PDF)

Letter (PDF)

Review (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s009lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761049Orig1s009ltr.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761049Orig1s009.pdf

05/14/2019 SUPPL-6 Supplement

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761049s006lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761049Orig1s006ltr.pdf

11/10/2020 SUPPL-5 Supplement

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761049Orig1s005ltr.pdf

10/19/2018 SUPPL-3 Supplement

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761049s003lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761049Orig1s003ltr.pdf

10/12/2017 SUPPL-2 Supplement

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s002lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761049Orig1s002ltr.pdf

04/25/2017 SUPPL-1 Supplement

Letter (PDF)

Label is not available on this site.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761049Orig1s001ltr.pdf

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
11/10/2020 SUPPL-5

Labeling-Medication Guide

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf
11/10/2020 SUPPL-5

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf
06/30/2020 SUPPL-9

Efficacy-New Indication

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s009lbl.pdf
05/14/2019 SUPPL-6

Efficacy-New Indication

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761049s006lbl.pdf
10/19/2018 SUPPL-3

Efficacy-New Dosing Regimen

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761049s003lbl.pdf
10/12/2017 SUPPL-2

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s002lbl.pdf
03/23/2017 ORIG-1 Approval

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf
برچسب‌ها:

نظرات کاربران